Adagio Therapeutics
overview of | Adagio Therapeutics
Company
Deck Type
Deck date
January 2023
Slide
3 of 10
Related slides by other companies
BenevolentAI
Results
March 2023
is a leading enabled drug discovery development company with a platform generated pipeline discovery development industry leading platform uncovers novel biology across diseases and drug modalities portfolio of in class and best in class programs discovered using our proprietary platform discovery preclinical clinical expansive knowledge graph with multimodal data foundations disease and drug modality agnostic generate predictions with the aim to increase the probability of success asset in phase assets in platform generated drug programmes enabled | BenevolentAI
OmniAb
Investor Presentation
May 2023
our business leveraging our proprietary discovery technology platform poised for growth to meet a global industry need | OmniAb
Nuvalent
Investor Presentation
January 2024
targeted therapies for patients with cancer parallel lead programs for clinical development proven discovery capabilities and alk in global research pipeline third program for her in enabling studies active hybrid operations with offices in listed growing team cash runway expected into | Nuvalent
Absci
Investor Presentation
October 2023
we are leveraging our platform advantages to create internal programs | Absci
Other recent decks by Adagio Therapeutics
See all presentations (12 decks)
Results
November 2023
Investor Presentation
June 2023
Investor Conference
June 2023
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights